Science & Technology

The pioneer company in human ES/iPS cell research for the entire world, from Japan

ReproCELL was founded in 2003 to develop the world-leading technologies of Professor Nakatsuji at Kyoto University and Professor Nakauchi at Tokyo University. ReproCELL’s own R&D team collaborates closely with top scientists and industry leaders to improve human health by providing innovative, unparalleled solutions.

ReproCELL’s core technologies

ReproCELL has played a pivotal role in commercializing the leading stem cell technologies developed by Japanese academia and industry. We have put a number of unprecedented original technologies into the market by collaborating closely with our partners.

Reprogramming technology developed by Kyoto University

ReproCELL is the first company licensed to generate iPS cells by reprogramming from iPS Academia Japan, which was established to advance healthcare through the transfer of the iPS technologies generated by Kyoto University. This made it possible for us to directly and quickly apply this innovative technology to applications in human health, by using it in combination with other world class technologies we have.

Human ES/iPS cell culture technology co-developed with Kyoto University

ReproCELL has commercialized culture medium for human ES/iPS cells as early as 2005. This medium was originally developed by company co-founder Professor Nakatsuji at Kyoto University. This medium, named `Primate ES Cell Medium` because human iPS cells had not yet been invented, has supported the entire ES/iPS cell research field for more than 6 years. One of the most famous studies made possible by this product was generation of the first human iPS cells by Professor Yamanaka at Kyoto University in 2007.  The team used Primate ES Cell Medium to establish the very first iPS cell line. ReproCELL has been continuously developing human ES/iPS cell culture technologies and has launched a number of culture reagents to help advance the field.

Human ES/iPS cell differentiation technology co-developed through national projects

ReproCELL’s strength lies not only in its technologies for maintaining ES/iPS cells, but also in its ability to generate functional human cells out of ES/iPS cells. Efficient methods to derive functional cardiomyocytes, neurons and hepatocytes have been developed through national projects spearheaded by ReproCELL and Professor Nakatsuji, and other collaborators. These world class cutting-edge stem cell technologies have been licensed to ReproCELL for further development as our own proprietary technologies. Thanks to these world class collaborations, ReproCELL can supply the best quality human functional cells in large amounts to support those who seek to improve human health throughout the world.

Disease model generation using human ES/iPS cells

y using the transgenic technology developed through the nationally-funded project by ReproCELL, Kyoto University, and many other collaborators, we can generate disease-model ES/iPS cells with known disease-related genes. Our iPS cell generation technology also enables the establishment of another type of disease model human iPS cells sourced from the tissues of patients. In combination with our proprietary technologies to derive functional cells from human ES/iPS cells, ReproCELL can supply a range of disease-model functional human cells that will be invaluable for promoting medical research in many fields.

Assay technologies to revolutionize medical research

ReproCELL has also been working hard to develop assay platforms to facilitate a wide range of researches including drug discovery and development. Our first application was QTempo, an in vitro cardiotoxicity test using cardiomyocytes, activity imaging of thin-layered cardiomyocytes, and dynamic activity monitoring of neurons. The combination of these technologies with our ability to derive unlimited amounts of human functional cells from ES/iPS cells will revolutionize the way medical research is performed for the first time in history, we can perform studies in human cells without worrying about limited cell supply, lot variation, and many other problems that have plagued research in the past.